CancerCast

Weill Cornell Medicine
  • 4.9 (29)
  • HEALTH & FITNESS

New scientific developments are transforming the future of cancer treatment and care. Hosted by world-renowned medical oncologist Dr. Manish Shah, CancerCast is your window into research breakthroughs, innovative therapies, and honest accounts of living with and beyond cancer.

  1. 2D AGO

    Understanding BiTE Immunotherapy: How Bispecific T-Cell Engagers Target Cancer

    Bispecific T-cell engager, or BiTE, therapy is an immunotherapy approach that helps the body’s own immune system target cancer cells by bringing immune cells and cancer cells together. In this episode of CancerCast, Dr. Manish Shah is joined by Dr. Mateo Mejia to explain how this form of antibody-based treatment works by directly connecting T cells and cancer cells. It is a new treatment in the arsenal of immunotherapy to treat cancer. They explore common side effects, as well as similarities and differences between BiTEs and other forms of immunotherapy. BiTE immunotherapy prevents cancer cells from being able to hide from the natural immune system, helping it to better recognize and attack the cancer. BiTEs are becoming an important treatment tool for several cancers, including multiple myeloma, lymphoma, lung cancer, and uveal melanoma. Drs. Shah and Mejia discuss the future direction and expansion of BiTE therapy, including ongoing research to bring these treatments to patients earlier in their cancer treatment journeys. Guest: Mateo Mejia Saldarriaga, MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and an Assistant Attending Physician at NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  2. FEB 13

    The Power of PSMA-Targeted Therapy for Prostate Cancer

    Prostate-specific membrane antigen, or PSMA, is a protein expressed on the surface of prostate cancer cells that has become an important target for both diagnosing and treating the disease. In this episode of CancerCast, Dr. Manish Shah speaks with prostate cancer expert Dr. Scott Tagawa about how this PSMA protein helps identify whether prostate cancer is confined to the prostate or has spread, and the ways it can be used to guide treatment decisions. They discuss how PSMA-based prostate cancer treatments work in the body and why these therapies have become one of the most significant recent advances in modern medicine for prostate cancer. Guest: Scott Tagawa, MD, MS, Director of the Genitourinary Oncology Program and Medical Director of the Genitourinary Oncology Research Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  3. JAN 14

    The Treatment Toolkit for Liver Cancer and Metastatic Disease, from Surgery to Shockwaves and Beyond

    Discover how liver cancer treatment is evolving in this episode of CancerCast. Dr. Manish Shah and Dr. Juan Rocca discuss the liver’s complicated and critical role in cancer care, from its position as a hotspot for metastasis to the role of the liver in impacting how well certain immunotherapy, chemotherapy and other cancer therapies will work. They explore the newest and most cutting-edge treatment options as part of a growing toolkit to personalize treatment for each patient, including open and robotic liver surgery, ablation, and no-cut technologies like histotripsy, using ultrasound shockwaves to liquefy liver tumors while sparing healthy tissue. The conversation also highlights the role and rise of liver transplantation for select cancers, such as colorectal cancer that has spread (metastasized) to the liver, in addition to tumors that start in the liver. There have been many recent treatment advances for both primary liver cancer and metastatic disease, and Drs. Rocca and Shah discuss how combining these new innovations with a team-based, multidisciplinary approach offers patients more options than ever before. Guest: Juan Rocca, MD, Surgical Director of the Weill Cornell Liver Cancer Program and an attending surgeon in the Division of Liver Transplantation and Hepatobiliary Surgery at NewYork-Presbyterian/Weill Cornell Medicine. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  4. 12/03/2025

    Key Insights from ASH 2025

    In this episode of CancerCast, Dr. Manish Shah is joined by Drs. Gail Roboz and Rick Furman, two internationally renowned Weill Cornell leaders in advancing therapies for leukemia and lymphoma, to preview groundbreaking research from the 2025 American Society of Hematology (ASH) Annual Meeting. Drs. Roboz and Furman highlight some of the most impactful abstracts to be presented during the meeting, detailing how these key research developments are poised to impact patients and the hematology field at-large. Tune in to hear more about the cutting-edge science with expert insights into how these innovations are transforming cancer care. The ASH annual meeting is the largest medical conference in the world dedicated to malignant and benign hematology, bringing together over 30,000 experts from around the world to share the latest research and advancements. Abstracts and studies discussed in this episode include PARADIGM, AML17, AML19, KOMET-007, CaDAnCe-101, CLL17, R-pola-glo, FLAIR, and more. Gail Roboz, MD, Director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Richard Furman, MD, Director of the Chronic Lymphocytic Leukemia (CLL) Research Center at Weill Cornell Medicine. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  5. 11/21/2025

    Liquid Biopsy: Cancer’s Clues in the Blood

    A liquid biopsy is a blood test that looks for cancer cells or genetic material, such as DNA, that are shed into the bloodstream in patients with cancer. In this episode of CancerCast, Dr. Massimo Cristofanilli and Dr. Manish Shah explore how liquid biopsies unlock real-time insights into cancer evolution through molecular diagnostics, painting a more comprehensive and holistic picture of what’s going on with cancer inside the body, and often much earlier than other imaging tools. By analyzing circulating tumor cells, cell-free DNA or circulating tumor DNA, liquid biopsies can offer many clues that may predict cancer recurrence, guide treatment decisions, or detect resistance to certain treatments. Learn more about how this evolving non-invasive technology enables more personalized care for patients. Guest: Massimo Cristofanilli, MD, Associate Director of Precision Oncology at the Weill Cornell Medicine Meyer Cancer Center (MCC), Co-Leader of the MCC Breast Cancer Disease Management Team and Scientific Director of the Englander Institute for Precision Medicine (EIPM) Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Learn more about Massimo Cristofanilli, MD.

  6. 10/28/2025

    Treatment Advances for Mismatch Repair Deficient Colon Cancer and Lynch Syndrome

    Mismatch repair deficiency is a condition caused by DNA errors in the body that lead to a high number of mutations, increasing cancer risk. Mismatch repair deficiency is also commonly associated with Lynch syndrome, an inherited genetic syndrome linked to higher rates of many cancers at younger ages, including colon cancer. In this episode of CancerCast, Dr. Manish Shah is joined by two guests, Drs. Frank Sinicrope and Steven Lipkin, to discuss mismatch repair deficient colon cancer and how this subset of colon cancer is managed and treated differently. Drs. Shah, Sinicrope, and Lipkin explain how immunotherapy can be particularly effective for colon cancer patients with mismatch repair deficiency, as well as related research and treatment developments. Tune in to learn more about the latest advances in managing mismatch repair-deficient colon cancer. Guests: Frank Sinicrope, MD, is a medical oncologist and researcher and the Mayo Clinic Rochester. Steven Lipkin, MD, a physician scientist at Weill Cornell Medicine and a board-certified geneticist. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  7. 09/22/2025

    Tumor-Infiltrating Lymphocytes (TIL) & Melanoma: A New Era of Treatment

    Tumor-infiltrating lymphocyte, or TIL, therapy is a new form of cellular immunotherapy that targets cancer cells by leveraging the body’s immune system and specialized cells called T-lymphocytes. This treatment is currently approved by the U.S. Food and Drug Administration (FDA) for metastatic melanoma with additional research ongoing in other types of cancer. Dr. Manish Shah spoke with melanoma expert Dr. Barbara Ma about how this treatment works, how it differs from other therapies, the logistics of this treatment process for patients, and more. Guest: Barbara Ma, MD, MS a medical oncologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

  8. 08/04/2025

    ASCO 2025 Highlights

    Drs. Manish Shah and Sarah Rutherford explore the groundbreaking research presented at the 2025 ASCO Annual Meeting. They discuss key developments from this year’s meeting, including new immunotherapy and targeted therapy options, the use of circulating tumor cell (ctDNA) and minimal residual disease (MRD) testing, the importance of selecting the right patients for the right treatments, and more. They also provide insights into how personalized and precision treatment options have the potential to reshape cancer care and minimize patients’ side effects. The American Society of Clinical Oncology, or ASCO, Annual Meeting is the largest oncology conference. Each year, the meeting brings together oncology experts, thought leaders and professionals from around the world to share cancer care insights and present state-of-the-art research poised to impact patient care. Guest: Sarah Rutherford, MD, a hematologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Host: Manish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

See All (73)

4.9
out of 5
29 Ratings

About

New scientific developments are transforming the future of cancer treatment and care. Hosted by world-renowned medical oncologist Dr. Manish Shah, CancerCast is your window into research breakthroughs, innovative therapies, and honest accounts of living with and beyond cancer.

Information

  • Creator
    Weill Cornell Medicine
  • Years Active
    2018 - 2026
  • Episodes
    73
  • Rating
    Clean
  • Copyright
    © Weill Cornell Medicine
  • Show Website
    CancerCast

More From Weill Cornell Medicine

You Might Also Like